Advertisement
Singapore markets open in 7 hours 19 minutes
  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     
  • S&P 500

    5,076.14
    +5.59 (+0.11%)
     
  • Dow

    38,497.91
    -5.78 (-0.02%)
     
  • Nasdaq

    15,743.14
    +46.50 (+0.30%)
     
  • Bitcoin USD

    64,987.67
    -1,749.57 (-2.62%)
     
  • CMC Crypto 200

    1,402.34
    -21.76 (-1.53%)
     
  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     
  • Gold

    2,337.60
    -4.50 (-0.19%)
     
  • Crude Oil

    82.57
    -0.79 (-0.95%)
     
  • 10-Yr Bond

    4.6580
    +0.0600 (+1.30%)
     
  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     
  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     
  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Novartis in Q3 2018: Analysts Expect Revenue Growth

Novartis in Q3 2018: Analysts Expect Revenue Growth

Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.